Figure S5 from RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer
Year: 2023
Type: other
Abstract: Patterns for post-study discontinuation therapies by first through third subsequent lines of treatment of the baseline EGFR-activating mutation subgroups. Sankey diagrams for (A) ex19del and (B) ex21L858R subgroups present therapies post-RAM+ERL and post-PBO+ERL study treatment discontinuation. Shown from left to right are first subsequent therapy, ie, second line of therapy; second subsequent therapy, ie, third line of therapy; and third or more subsequent lines of therapy, ie, fourth or more lines of therapy. Therapies are subgrouped by color family as follows: EGFR-TKIs (erlotinib, osimertinib, EGFR-TKI plus VEGF and other EGFR-TKI) in green; platinum-based chemotherapy with or without VEGF inhibitor in red; non-platinum-based chemotherapy with or without VEGF inhibitor) in purple; and immunotherapy or investigational drugs in brown. Further details on post-study discontinuation therapies are provided in Supplementary Table S5.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4379985795